Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
autoimmune disease
Biotech
Beeline bolsters autoimmune ambitions with $126M
The funds come from existing backers Bain Capital, the Canada Pension Plan Investment Board and BMS, which also provided the biotech's five programs.
Darren Incorvaia
Jun 30, 2026 7:00am
Moderna enters in vivo CAR-T with autoimmune asset
Jun 26, 2026 9:00am
With $15M, BI becomes latest to buy into Immunai’s AI platform
Jun 25, 2026 9:00am
Sanofi halts phase 3 autoimmune trial early over lackluster data
Jun 10, 2026 4:25am
Boehringer makes €407M bet on Immunitas’ inflammatory asset
May 12, 2026 9:57am
UCB inks $2B Candid buyout to join Gilead in autoimmune field
May 4, 2026 7:46am
